Abstract Background Dopamine agonists (DAs) are efficacious for the treatment of motor and nonmotor symptoms in patients with Parkinson’s disease (PD). The treatment of PD with DAs is often complicated by adverse drug reactions (ADRs) of dopaminergic and non-dopaminergic origins. The DA piribedil is widely used in Asian, European, and Latin American countries; therefore, its ADRs are pertinent to clinicians. Here we present a rare case of hypotension and bradycardia that is significantly related to the dosage of piribedil. Case presentation A middle-aged male, diagnosed with PD, received dopamine replacement with piribedil. When taking 50 mg piribedil daily dose, the patient didn’t feel any discomfort. Two hours after taking 100 mg piribedi...
Background: There is growing evidence that ergot dopamine agonists may induce cardiac valve regurgit...
Recent studies related angiotensin converting enzyme (ACE) inhibitors and calcium channel blockers t...
Background: There is growing evidence that ergot dopamine agonists may induce cardiac valve regurgit...
Dopamine agonists are well-established symptomatic medications for treating early and advanced Parki...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
Background: Piribedil is a non-ergot D2/D3 dopamine agonist with antagonistic effect on α2-adrenocep...
Introduction: Dopamine agonists (DAs) are frequently used to treat early or advanced Parkinson’s dis...
International audienceBACKGROUND: Sleep attacks were initially described in 1999 in patients with Pa...
Impulse control disorders (ICD) in Parkinson's disease (PD) have attracted increasing interest. They...
Piribedil is a non-ergoline, dopamine D(2)/D(3) receptor agonist with α(2) adrenoceptor antagonist p...
The hemodynamic and biochemical effects of cabergoline, a new ergoline derivative with selective, po...
Background: Epidemiological studies report an association of ventricular arrhythmias with medicatio...
The aim of present study was to investigate the risk of heart failure associated with dopamine agoni...
Background: There is growing evidence that ergot dopamine agonists may induce cardiac valve regurgit...
The aim of present study was to investigate the risk of heart failure associated with dopamine agoni...
Background: There is growing evidence that ergot dopamine agonists may induce cardiac valve regurgit...
Recent studies related angiotensin converting enzyme (ACE) inhibitors and calcium channel blockers t...
Background: There is growing evidence that ergot dopamine agonists may induce cardiac valve regurgit...
Dopamine agonists are well-established symptomatic medications for treating early and advanced Parki...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
Background: Piribedil is a non-ergot D2/D3 dopamine agonist with antagonistic effect on α2-adrenocep...
Introduction: Dopamine agonists (DAs) are frequently used to treat early or advanced Parkinson’s dis...
International audienceBACKGROUND: Sleep attacks were initially described in 1999 in patients with Pa...
Impulse control disorders (ICD) in Parkinson's disease (PD) have attracted increasing interest. They...
Piribedil is a non-ergoline, dopamine D(2)/D(3) receptor agonist with α(2) adrenoceptor antagonist p...
The hemodynamic and biochemical effects of cabergoline, a new ergoline derivative with selective, po...
Background: Epidemiological studies report an association of ventricular arrhythmias with medicatio...
The aim of present study was to investigate the risk of heart failure associated with dopamine agoni...
Background: There is growing evidence that ergot dopamine agonists may induce cardiac valve regurgit...
The aim of present study was to investigate the risk of heart failure associated with dopamine agoni...
Background: There is growing evidence that ergot dopamine agonists may induce cardiac valve regurgit...
Recent studies related angiotensin converting enzyme (ACE) inhibitors and calcium channel blockers t...
Background: There is growing evidence that ergot dopamine agonists may induce cardiac valve regurgit...